Business
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
ZUG, Switzerland, February 18, 2025--Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or cal
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/1ffe5e6b387d39c005d5d7d8b1fea2a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D.NTjcmEXehCDBLHzzMMZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1ffe5e6b387d39c005d5d7d8b1fea2a5","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zfqa6PFJcHPPDrSRK9PqTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1ffe5e6b387d39c005d5d7d8b1fea2a5","width":823,"height":209}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the remaining countries – Australia and Singapore","length":193,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nemolizumab, which is also approved in the EU and U.S., is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in both moderate-to-severe atopic dermatitis and prurigo nodularis1-6","length":310,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":503,"olType":false},{"type":"text","content":"ZUG, Switzerland, February 18, 2025--(BUSINESS WIRE)--Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years of age and older with a body weight of at least 30kg, who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.7,8","length":805,"tagName":"p"},{"type":"text","content":"These are the fir...